P ROLONGED REMISSIONS in chronic myeloid leukemia following treatment with busulfan have been reported by various authors.’-” Although lengthy periods of latency of the disease following cytostatic treatment are not uncommon, the observation of a complete clinical and hematologic remission of nearly 7 years duration in a patient with chronic myeloid leukemia following a single course of busulfa...

background: advancement in the treatment of various types of cancer has led to greater patient survival. these treatments essentially have toxic effects on different kinds of cells, such as germ cells. infertility as one of the side effects of cancer treatment has changed the quality of life of young cancer survivors dramatically. melatonin is an antioxidant with receptors in the reproductive s...

A 24-year-old woman with advanced Hodgkin disease received the standard dosing protocol for busulfan/cyclophosphamide before autologous hematopoietic stem cell transplantation (HSCT) 4 from a matched unrelated donor. The target area under the plasma concentration vs time curve (AUC) for busulfan was set at 950 μmol · L -1 · min -1 , near the low end of the therapeutic interval of 900–1350 μmol ...

1. O’Brien SG, Goldman JM: Busulfan alone as cytoreduction before autografting for chronic myelogenous leukemia. Blood 91:1091, 1998 (letter) 2. Down JD, Ploemacher RE: Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: Differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol 21:913, 1993 3. Down JD, Boudewijn A, van O...

Successful spermatogonial transplantation requires depletion of the host germ cells to allow efficient colonization of the donor spermatogonial stem cells. Although a sterilizing drug, busulfan (Myleran), is commonly used for preparing a recipient mouse before transplantation, the optimal dose of this drug has not yet been defined. The present study investigated the effects of different doses o...

A Phase I-II clinical trial of high dose single agent busulfan (16-20 mg/kg) administered over a 4-day period was undertaken. Pharmacokinetic measurements reveal that steady state total plasma busulfan levels between 2 and 10 microM were achieved by the second day and maintained through the remaining treatment period. Urinary excretion of mutagenic activity monitored by the Salmonella mutagenes...

Hepatic venoocclusive disease (HVOD) in bone marrow transplantation (BMT) is attributed to toxicity of cytoreductive agents, especially busulfan and cyclophosphamide, in the conditioning therapy. Busulfan, as well as the metabolites of cyclophosphamide, are conjugated with glutathione (GSH), catalyzed by enzymes of the glutathione S-transferase (GST) family. To assess the impact of polymorphism...

AIM OF THE STUDY Resistance to imatinib is one of the most important issues in treatment of chronic myeloid leukemia (CML) patients. The objective of the study was to analyze the ex vivo drug resistance profile to bortezomib and 22 other antileukemic drugs, including three tyrosine kinase inhibitors (TKIs), in CML in comparison to acute myeloid leukemia (AML). MATERIAL AND METHODS A total of ...

The pharmacokinetics of busulfan, given as a single daily dose (either 4 mg/kg or 150 mg/m2), was determined in 22 children undergoing bone marrow transplantation for acute leukemia. The single daily dose regimen showed similar pharmacokinetics to previously reported regimens of 4 x 1 mg/kg, except for fourfold higher mean peak plasma levels and negligible trough levels. Daily systemic exposure...